Anixa Biosciences (NASDAQ:ANIX) CEO Acquires $15,200.00 in Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar acquired 5,000 shares of the firm’s stock in a transaction on Friday, July 10th. The shares were bought at an average cost of $3.04 per share, for a total transaction of $15,200.00. Following the acquisition, the chief executive officer owned 635,812 shares in the company, valued at approximately $1,932,868.48. The trade was a 0.79% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Amit Kumar also recently made the following trade(s):

• On Friday, June 12th, Amit Kumar bought 21,000 shares of Anixa Biosciences stock. The stock was bought at an average cost of $2.50 per share, with a total value of $52,500.00.

Anixa Biosciences Trading Up 9.7%

Shares of ANIX stock opened at $3.50 on Thursday. Anixa Biosciences Inc has a 1 year low of $2.32 and a 1 year high of $5.46. The firm’s 50 day moving average is $2.81 and its 200-day moving average is $2.90. The firm has a market capitalization of $119.08 million, a price-to-earnings ratio of -11.29 and a beta of 0.59.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. On average, equities research analysts forecast that Anixa Biosciences Inc will post -0.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ANIX shares. Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. HC Wainwright reaffirmed a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Anixa Biosciences in a research report on Wednesday, June 17th. Finally, D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday, June 30th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Anixa Biosciences currently has an average rating of “Hold” and an average price target of $8.50.

Institutional Investors Weigh In On Anixa Biosciences

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Anixa Biosciences by 2.1% during the third quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company’s stock worth $4,694,000 after purchasing an additional 29,436 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Anixa Biosciences by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock valued at $1,095,000 after buying an additional 7,271 shares in the last quarter. Bank of America Corp DE increased its position in shares of Anixa Biosciences by 1.7% in the 3rd quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock valued at $706,000 after buying an additional 3,645 shares in the last quarter. State Street Corp raised its stake in Anixa Biosciences by 32.0% during the 4th quarter. State Street Corp now owns 159,040 shares of the company’s stock worth $496,000 after buying an additional 38,540 shares during the period. Finally, 683 Capital Management LLC acquired a new stake in Anixa Biosciences during the 4th quarter worth $355,000. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.